24. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 18, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

25. A pharmaceutical composition according to claim 24, additionally comprising other active ingredients.

26. An antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25 for use as a medicament.

27. An antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25 for the treatment of cancer.

28. An antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25, for the treatment of fibrotic disease.

29. The use of an antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25 in the manufacture of a medicament for the treatment or prophylaxis of cancer.

30. The use of an antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25 in the manufacture of a medicament for the treatment or prophylaxis of fibrotic disease.

~~31. A method for the treatment of a human subject suffering from or at risk of cancer, the method comprising administering to the subject an effective amount of an anti-CSF-1R antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25.~~

~~32. A method for the treatment of a human subject suffering from or at risk of fibrotic disease, the method comprising administering to the subject an effective amount of an anti-CSF-1R antibody according to any one of claims 1 to 18 or a composition according to claim 24 or 25.~~

~~33~~31. The antibody for use according to claim 27~~,~~ or the use according to claim 29 ~~or the method according to claim 31~~, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer.

~~34~~32. The antibody for use according to claim 28~~,~~ or the use according to claim 30 ~~or the method according to claim 32~~, wherein the fibrotic disease is selected from the group consisting of pulmonary fibrosis such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis, liver cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloid, myocardial infarction, scleroderma and arthofibrosis.